Pancreatic Cancer - Pipeline Review, H2 2018

Global Markets Direct’s, ‘Pancreatic Cancer - Pipeline Review, H2 2018’, provides an overview of the Pancreatic Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Pancreatic Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pancreatic Cancer and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Pancreatic Cancer

- The report reviews pipeline therapeutics for Pancreatic Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Pancreatic Cancer therapeutics and enlists all their major and minor projects

- The report assesses Pancreatic Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Pancreatic Cancer

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Pancreatic Cancer

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Pancreatic Cancer pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

3-V Biosciences Inc

4P-Pharma SAS

4SC AG

AB Science SA

AbbVie Inc

AbGenomics International Inc

Ability Pharmaceuticals SL

Aclaris Therapeutics Inc

Actuate Therapeutics Inc

Adamed ...

3-V Biosciences Inc

4P-Pharma SAS

4SC AG

AB Science SA

AbbVie Inc

AbGenomics International Inc

Ability Pharmaceuticals SL

Aclaris Therapeutics Inc

Actuate Therapeutics Inc

Adamed Sp z oo

ADC Therapeutics SA

Aduro BioTech Inc

Advanced BioDesign

Advantagene Inc

Advanz Pharmaceutical Corp

Advenchen Laboratories LLC

Agency for Science, Technology and Research

AGV Discovery SAS

AIMM Therapeutics BV

Alissa Pharma

Alligator Bioscience AB

Allinky Biopharma SL

Almac Discovery Ltd

Altor BioScience Corp

ALX Oncology Inc

Ambrx Inc

amcure GmbH

Amgen Inc

Amplia Therapeutics Ltd

Anavex Life Sciences Corp

Andarix Pharmaceuticals Inc

ANP Technologies Inc

AntiCancer Inc

APEIRON Biologics AG

Apexigen Inc

Aphios Corp

Aposense Ltd

Aravive Inc

ArQule Inc

Array BioPharma Inc

Asana BioSciences LLC

Ascelia Pharma AB

Astellas Pharma Inc

AstraZeneca Plc

Aurigene Discovery Technologies Ltd

AVEO Pharmaceuticals Inc

Axcentua Pharmaceuticals AB

Basilea Pharmaceutica Ltd

Batu Biologics Inc

Bavarian Nordic A/S

Bayer AG

BeiGene Ltd

Bellicum Pharmaceuticals Inc

Berg LLC

BerGenBio ASA

Bexion Pharmaceuticals LLC

BeyondSpring Inc

Bio-Path Holdings Inc

BioAtla LLC

Biokine Therapeutics Ltd

BioLineRx Ltd

BioMoti Ltd

Biomunex Pharmaceuticals

Biothera Pharmaceutical Inc

Biouniversa srl

BioXcel Therapeutics Inc

BLR Bio LLC

Boehringer Ingelheim GmbH

Boston Biomedical Inc

BriaCell Therapeutics Corp

Bristol-Myers Squibb Co

Cancer Prevention Pharmaceuticals Inc

Canget BioTekpharma LLC

Cantargia AB

Cantex Pharmaceuticals Inc

CARsgen Therapeutics Ltd

CBM BioPharma Inc

CBT Pharmaceuticals Inc

CCRP Therapeutics GmbH

Celgene Corp

Celldex Therapeutics Inc

Cellectar Biosciences Inc

Celleron Therapeutics Ltd

Cellular Biomedicine Group Inc

Celprogen Inc

Celyad SA

Centrose LLC

ChemoCentryx Inc

Chugai Pharmaceutical Co Ltd

Clovis Oncology Inc

COARE Biotechnology Inc

Codiak BioSciences Inc

Corcept Therapeutics Inc

Cotinga Pharmaceuticals Inc

CPL Biologicals Pvt Ltd

CrystalGenomics Inc

CTI BioPharma Corp

Cyclacel Pharmaceuticals Inc

CytImmune Sciences Inc

Cytori Therapeutics Inc

CyTuVax BV

Daiichi Sankyo Co Ltd

DEKK-TEC Inc

Delta-Fly Pharma Inc

Denceptor Therapeutics Ltd

Diffusion Pharmaceuticals Inc

Eisai Co Ltd

Eleison Pharmaceuticals LLC

Eli Lilly and Co

Endor Technologies SL

Enterome Bioscience SA

Erytech Pharma SA

Esperance Pharmaceuticals Inc

Etubics Corp

Exelixis Inc

F. Hoffmann-La Roche Ltd

Faron Pharmaceuticals Oy

Felicitex Therapeutics Inc

FibroGen Inc

Forbius

Formosa Laboratories Inc

Table of Contents

Table of Contents

Table of Contents 2

Introduction 14

Pancreatic Cancer - Overview 15

Pancreatic Cancer - Therapeutics Development 16

Pancreatic Cancer - Therapeutics Assessment 94

Pancreatic Cancer ...

Table of Contents

Table of Contents 2

Introduction 14

Pancreatic Cancer - Overview 15

Pancreatic Cancer - Therapeutics Development 16

Pancreatic Cancer - Therapeutics Assessment 94

Pancreatic Cancer - Companies Involved in Therapeutics Development 135

Pancreatic Cancer - Drug Profiles 289

Pancreatic Cancer - Dormant Projects 2665

Pancreatic Cancer - Discontinued Products 2694

Pancreatic Cancer - Product Development Milestones 2700

Appendix 2711

List of Tables

List of Tables

Number of Products under Development for Pancreatic Cancer, H2 2018 91

Number of Products under Development by Companies, H2 2018 93

Number ...

List of Tables

Number of Products under Development for Pancreatic Cancer, H2 2018 91

Number of Products under Development by Companies, H2 2018 93

Number of Products under Development by Universities/Institutes, H2 2018 118

Products under Development by Companies, H2 2018 123

Products under Development by Universities/Institutes, H2 2018 163

Number of Products by Stage and Target, H2 2018 170

Number of Products by Stage and Mechanism of Action, H2 2018 188

Number of Products by Stage and Route of Administration, H2 2018 206

Number of Products by Stage and Molecule Type, H2 2018 209

Pancreatic Cancer - Pipeline by 3-V Biosciences Inc, H2 2018 210

Pancreatic Cancer - Pipeline by 4P-Pharma SAS, H2 2018 210

Pancreatic Cancer - Pipeline by 4SC AG, H2 2018 211

Pancreatic Cancer - Pipeline by AB Science SA, H2 2018 211

Pancreatic Cancer - Pipeline by AbbVie Inc, H2 2018 212

Pancreatic Cancer - Pipeline by AbGenomics International Inc, H2 2018 212

Pancreatic Cancer - Pipeline by Ability Pharmaceuticals SL, H2 2018 213

Pancreatic Cancer - Pipeline by Aclaris Therapeutics Inc, H2 2018 213

Pancreatic Cancer - Pipeline by Actuate Therapeutics Inc, H2 2018 214

Pancreatic Cancer - Pipeline by Adamed Sp z oo, H2 2018 214

Pancreatic Cancer - Pipeline by ADC Therapeutics SA, H2 2018 214

Pancreatic Cancer - Pipeline by Aduro BioTech Inc, H2 2018 215

Pancreatic Cancer - Pipeline by Advanced BioDesign, H2 2018 215

Pancreatic Cancer - Pipeline by Advantagene Inc, H2 2018 216

Pancreatic Cancer - Pipeline by Advanz Pharmaceutical Corp , H2 2018 216

Pancreatic Cancer - Pipeline by Advenchen Laboratories LLC, H2 2018 217

Pancreatic Cancer - Pipeline by Agency for Science, Technology and Research, H2 2018 217

Pancreatic Cancer - Pipeline by AGV Discovery SAS, H2 2018 217

Pancreatic Cancer - Pipeline by AIMM Therapeutics BV, H2 2018 218

Pancreatic Cancer - Pipeline by Alissa Pharma, H2 2018 218

Pancreatic Cancer - Pipeline by Alligator Bioscience AB, H2 2018 219

Pancreatic Cancer - Pipeline by Allinky Biopharma SL, H2 2018 219

Pancreatic Cancer - Pipeline by Almac Discovery Ltd, H2 2018 219

Pancreatic Cancer - Pipeline by Altor BioScience Corp, H2 2018 220

Pancreatic Cancer - Pipeline by ALX Oncology Inc, H2 2018 220

Pancreatic Cancer - Pipeline by Ambrx Inc, H2 2018 220

Pancreatic Cancer - Pipeline by amcure GmbH, H2 2018 221

Pancreatic Cancer - Pipeline by Amgen Inc, H2 2018 221

Pancreatic Cancer - Pipeline by Amplia Therapeutics Ltd, H2 2018 222

Pancreatic Cancer - Pipeline by Anavex Life Sciences Corp, H2 2018 222

Pancreatic Cancer - Pipeline by Andarix Pharmaceuticals Inc, H2 2018 223

Pancreatic Cancer - Pipeline by ANP Technologies Inc, H2 2018 223

Pancreatic Cancer - Pipeline by AntiCancer Inc, H2 2018 223

Pancreatic Cancer - Pipeline by APEIRON Biologics AG, H2 2018 224

Pancreatic Cancer - Pipeline by Apexigen Inc, H2 2018 224

Pancreatic Cancer - Pipeline by Aphios Corp, H2 2018 224

Pancreatic Cancer - Pipeline by Aposense Ltd, H2 2018 225

Pancreatic Cancer - Pipeline by Aravive Inc, H2 2018 225

Pancreatic Cancer - Pipeline by ArQule Inc, H2 2018 226

Pancreatic Cancer - Pipeline by Array BioPharma Inc, H2 2018 226

List of Figures

List of Figures

Number of Products under Development for Pancreatic Cancer, H2 2018 91

Number of Products under Development by Companies, H2 2018 92

Number ...

List of Figures

Number of Products under Development for Pancreatic Cancer, H2 2018 91

Number of Products under Development by Companies, H2 2018 92

Number of Products under Development by Universities/Institutes, H2 2018 118

Number of Products by Top 10 Targets, H2 2018 169

Number of Products by Stage and Top 10 Targets, H2 2018 169

Number of Products by Top 10 Mechanism of Actions, H2 2018 187

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018 187

Number of Products by Top 10 Routes of Administration, H2 2018 205

Number of Products by Stage and Top 10 Routes of Administration, H2 2018 205

Number of Products by Top 10 Molecule Types, H2 2018 208

Number of Products by Stage and Top 10 Molecule Types, H2 2018 208

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports